Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
09 août 2018 16h10 HE
|
Asterias Biotherapeutics
Company Progressing Neurology and Immunotherapy Clinical Programs Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the...
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
31 juil. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
26 juil. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
17 juil. 2018 07h00 HE
|
Asterias Biotherapeutics
- Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury...
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
12 juil. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
11 juil. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
12 juin 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury
05 juin 2018 07h00 HE
|
Asterias Biotherapeutics
- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to...
Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
16 mai 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
09 mai 2018 16h12 HE
|
Asterias Biotherapeutics
- AST-VAC2 Immunotherapy Program Prepares to Enter Clinic in Second Quarter of 2018 – - Conference Call and Webcast Today, May 9, at 5:00 p.m. ET – FREMONT, Calif., May 09, 2018 (GLOBE NEWSWIRE)...